Kyverna Therapeutics plans to submit a personalized CAR-T cell therapy for stiff person syndrome to the FDA for approval, which, if granted, would be the first treatment for this rare autoimmune disease and the first personalized CAR-T therapy for any autoimmune condition. The therapy has shown promise in improving mobility and reducing disabilities in affected patients.
Kyverna Therapeutics is on the cusp of submitting a groundbreaking personalized CAR-T cell therapy for FDA approval, targeting stiff person syndrome, a rare autoimmune disease. If approved, this would mark the first instance of a CAR-T therapy being used for an autoimmune condition, potentially opening new markets and applications for CAR-T technologies beyond oncology. This development signals a pivotal shift in the biotech industry towards leveraging personalized medicine for complex autoimmune disorders.